3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Cancer Pain
2
Solid Tumor, Adult
1
Medication Adherence
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Gastrointestinal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor, Adult
×
Pharmaceutical Services
×
Clear all
NCT04175899
2021-03-08
POCCP1
Ministry of Health, Malaysia
Phase NA
Unknown
106 enrolled